A study of some rhodium(II) acetate adducts

Unlocking catalytic potential: a rhodium(II)-based coordination polymer for efficient carbene transfer reactions with donor/acceptor diazoalkanes

Herein, we report the use of a molecular-defined rhodium(II) coordination polymer (Rh-CP) as a heterogeneous, recyclable catalyst in carbene transfer reactions. We showcase the application of this heterogeneous catalyst in a range of carbene transfer reactions and conclude with the functionalization of natural products and drug molecules.

Binding of histidine and human serum albumin to dirhodium(II) tetraacetate

Reactions of the anticancer active dirhodium tetraacetate (1), Rh₂(AcO)₄ (AcO^- = CH₃COO^-), with the amino acid histidine (HHis) and human serum albumin (HSA) were monitored over time and different metal: ligand ratios using UV-vis spectroscopy and/or electro-spray ionization mass spectrometry. Initially, histidine formed 1:1 and 1:2 adducts in aqueous solutions. The crystal structure of Rh₂(AcO)₄(L-HHis)₂·2H₂O (2) confirmed the axial coordination of histidine imidazole groups (average Rh-N_axial 2.23 Å). These adducts, however, were found to be unstable in solution over time (24 h). Heating Rh₂(AcO)₄ -histidine solutions to 40 °C (near body temperature) or 95 °C accelerated the formation of Rh^II₂(AcO)₂(His)₂ and Rh^III(His)₂(AcO) complexes. The corresponding pH change from neutral to mildly acid (pH 4-5) indicates deprotonation of histidine NH₃⁺ groups due to coordination to Rh ions, which simultaneously bind to histidine COO^- groups, as evidenced by ¹³C NMR spectroscopy. In the case of HSA with 16 histidine and one cysteine residues, UV-vis spectroscopy indicates that mono- and di-histidine HSA adducts with Rh₂(AcO)₄ are formed. X-ray absorption spectroscopy showed almost the same Rh-Rh distance (2.41 ± 0.01 Å) for the Rh₂(AcO)₄ units as in 2, and a contribution from an axial thiol coordination (Rh-S_axial 2.62 ± 0.05 Å). The Rh₂(AcO)₄ - HSA complex was found to decompose partially (~15%) over 24 h at ambient temperature. The partial decomposition of Rh₂(AcO)₄ both through coordination to histidine or to human serum albumin, the most abundant protein in blood plasma, is a factor to consider for its efficacy as a potential anticancer agent.

Reactions of Rh2(CH3COO)4 with thiols and thiolates: a structural study

The structural differences between the aerobic reaction products of Rh2(AcO)4 (1; AcO- = CH3COO-) with thiols and thiolates in non-aqueous media are probed by X-ray absorption spectroscopy. For this study, ethanethiol, dihydrolipoic acid (DHLA; a dithiol) and their sodium thiolate salts were used. Coordination of simple thiols to the axial positions of Rh2(AcO)4 with Rh-SH bonds of 2.5-2.6 Å keeps the RhII-RhII bond intact (2.41 ± 0.02 Å) but leads to a colour change from emerald green to burgundy. Time-dependent density functional theory (TD-DFT) calculations were performed to explain the observed shifts in the electronic (UV-vis) absorption spectra. The corresponding sodium thiolates, however, break up the Rh2(AcO)4 framework in the presence of O2 to form an oligomeric chain of triply S-bridged Rh(III) ions, each with six Rh-S (2.36 ± 0.02 Å) bonds. The RhIII...RhIII distance, 3.18 ± 0.02 Å, in the chain is similar to that previously found for the aerobic reaction product from aqueous solutions of Rh2(AcO)4 and glutathione (H3A), {Na2[Rh2III(HA)4]·7H2O}n, in which each Rh(III) ion is surrounded by about four Rh-S (2.33 ± 0.02 Å) and about two Rh-O (2.08 ± 0.02 Å). The reaction products obtained in this study can be used to predict how dirhodium(II) tetracarboxylates would react with cysteine-rich proteins and peptides, such as metallothioneins.

Rh(II)-mediated domino [4 + 1]-annulation of α-cyanothioacetamides using diazoesters: A new entry for the synthesis of multisubstituted thiophenes

A new approach towards the synthesis of multisubstituted thiophenes is elaborated based on Rh(II)-catalyzed domino reactions of acyclic diazoesters with α-cyanothioacetamides. It provides a way for the preparation of 5-amino-3-(alkoxycarbonylamino)thiophene-2-carboxylates, 2-(5-amino-2-methoxycarbonylthiophene-3-yl)aminomalonates and (2-cyano-5-aminothiophene-3-yl)carbamates with the preparative yields of up to 67%. It was also shown that α-cyanothioacetamides easily interact with dirhodium carboxylates to give rather stable 2:1 complexes, resulting in an evident decrease in the efficiency of the catalytic process at moderate temperatures (20–30 °C).

Evaluation of a new protocol for enzymatic dynamic kinetic resolution of 3-hydroxy-3-(aryl)propanoic acids

The application of tandem metal–enzyme dynamic kinetic resolution (DKR) is a powerful tool for the manufacture of high-value chemical commodities.

Chemoselective tryptophan labeling with rhodium carbenoids at mild pH

Significant improvements have been made to a previously reported tryptophan modification method using rhodium carbenoids in aqueous solution, allowing the reaction to proceed at pH 6-7. This technique is based on the discovery that N-(tert-butyl)hydroxylamine promotes indole modification with rhodium carbenoids over a broad pH range (2-7). This methodology was demonstrated on peptide and protein substrates, generally yielding 40-60% conversion with excellent tryptophan chemoselectivity. The solvent accessibility of the indole side chains was found to be a key factor in successful carbenoid addition, as demonstrated by conducting the reaction at temperatures high enough to cause thermal denaturation of the protein substrate. Progress toward the expression of proteins bearing solvent accessible tryptophan residues as reactive handles for modification with rhodium carbenoids is also reported.

Rhodium and its compounds as potential agents in cancer treatment

The antitumor activity of the inorganic complex cis-diammine-dichloroplatinum(II) (cisplatin) led to the development of other types of non-organic cytostatic drugs. Numerous platinum other platinum and non-platinum metal compounds were shown to be effective against animal model tumors as well as tumors in man. However, the introduction of novel transition metal agents in clinical treatment is exceptionally slow. So far, Ru(II) and Ru(III) complexes have shown very promising properties while the Ru(III) compound, [ImH][trans-Cl4(Me2SO)(Im)Ru(III)] (Im=imidazole, NAMI-A), is the first ruthenium compound that successfully entered phase I clinical trials. Rhodium belongs to the same group as platinum and ruthenium. However, rhodium compounds, analogues to the corresponding platinum and ruthenium compounds that possess significant antitumor properties, were found to be less effective as anticancer agents mainly due to their toxic effects. Dimeric mu-Acetato dimers of Rh(II) as well as monomeric square planar Rh(I) and octahedral Rh(III) complexes have shown interesting antitumor properties.

Interaction of tetra-mu-acetatodirhodium(II) with human serum albumin

The interaction of Rh2(OAc)4 with human serum albumin (HSA) has been studied by absorption difference spectroscopy, CD spectroscopy, and quantitative precipitating HSA-antibody test. Our results demonstrate that this rhodium complex reacts easily with HSA at several ratios of reagents. The Rh atoms are coordinated to protein molecules via the imidazole rings of His residues. The structural studies have shown the conformational change of HSA modified by rhodium. Rhodium binding lowers the helicity of the native protein between 8 to 18% depending upon the molar ratios (from 1:1 to 10:1). Denaturation measurements of free HSA and HSA in the presence of dirhodium(II) acetate complex with 8-M urea followed by CD spectroscopy, suggest that rhodium affects the secondary protein structure and might stabilize HSA against denaturing agents. 8-M urea caused the unfolding of the native HSA secondary structure by about 40% and the structure of Rh(OAc)4-HSA by about 10%. The modification of native HSA by rhodium causes its decreased ability to precipitate with HSA antibodies. The decrease of antigenic properties can be connected with the unfolding of the antigen structure, which brings about perturbation of complementarity of the antigen-antibody reactive sites.

The interaction between radiation and complexes of cis-Pt(II) and Rh(II): studies at the molecular and cellular level

A range of Rh(II) carboxylates and cis-Pt(II) complexes have been examined for their ability to increase the radiation sensitivity of aerobic and hypoxic V79 cells in vitro. The transition metal complexes sensitize in both air and nitrogen, with the greater effect generally occurring in nitrogen. The cis-Pt(II) complexes only show small levels of sensitization with dose modification factors (DMFs) of no more than 1.2. In contrast, the Rh(II) complexes can give DMFs of 2.0. Radiation chemical experiments show the transition metal complexes to have substantially lower redox potentials than metronidazole and, in addition, neither type of complex undergoes electron transfer reaction or adduct formation on interaction with radicals derived from DNA bases. Thus, the inorganic complexes do not operate by mechanisms similar to those occurring with electron affinic or stable free radical sensitizers. The increase in radiation sensitivity for cells treated with the Rh(II) carboxylates, but not the cis-Pt(II) complexes, is attributed to the ability of the Rh compounds to deplete intracellular thiols. Further, the efficiency of sensitization by the Rh(II) complexes and their ability to interact with cellular thiols depends upon the nature of the carboxylate ligand and follows the order butyrate greater than propionate greater than acetate greater than methoxyacetate. The differences between the carboxylates may be due to differences in drug uptake. A combination of the Rh(II) complexes with misonidazole given to hypoxic cells irradiated in vitro gives an additive response. However, it was not possible to demonstrate a similar effect in tumours in mice given the combination of Rh(II) methoxyacetate and the misonidazole analogue RSU 1070.